QIAGEN N.V. To Announce Third Quarter 2013 Financial Results

VENLO, The Netherlands, Oct. 9, 2013 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today reconfirmed plans to release its report on results for the third quarter of 2013 on Tuesday, October 29, at 21:00 Central European Time (CET) / 16:00 Eastern Time (ET).

Also as previously announced, a conference call is planned for Wednesday, October 30, at 14:30 CET / 9:30 ET that will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

Conference Call & Webcast Details

The conference call will begin at 14:30 CET / 9:30 ET on October 30, 2013. Interested parties may listen to the call by dialing:

+1 855 272 3518 (US), +44 (0) 203 059 5869 (UK), +49 (0) 69 566 036 000 (Germany)

The webcast will be accessible at www.qiagen.com/About-Us/Investors/Events-and-Presentations/Conference-Calls .

A replay of the conference call will be available through November 6, 2013, by dialing:

+1 866 268 1947 (US), +44 (0) 121 260 4861, +49 (0) 69 710 488 70 (passcode: 880832#).

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of June 30, 2013, QIAGEN employed approximately 4,050 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com .
CONTACT: IR@qiagen.com

QIAGEN N.V. Logo

If you liked this article you might like

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

3 Diversified Services Stocks Nudging The Industry Higher

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Watch Out: Barbarians At The Gate For Qiagen (QGEN)